menu
    • menu

    Company profile for Kaerus Bioscience

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kaerus Bioscience is dedicated to discovering and developing targeted therapeutics for rare neurodevelopmental disorders. By leveraging the latest advances in human genetics, the company is at the forefront of creating innovative treatments for genetic syndromes, such as Fragile X Syndrome. With a focus on precision medicine, Kaerus aims to address the unmet needs of patients with these challenging conditions, where traditiona...
    Kaerus Bioscience is dedicated to discovering and developing targeted therapeutics for rare neurodevelopmental disorders. By leveraging the latest advances in human genetics, the company is at the forefront of creating innovative treatments for genetic syndromes, such as Fragile X Syndrome. With a focus on precision medicine, Kaerus aims to address the unmet needs of patients with these challenging conditions, where traditional treatments have been limited or ineffective.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kaerus Bioscienceunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    2nd Floor 168 Shoreditch High Street, London
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kaerusbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Servier Acquires Potential Treatment for Fragile X Syndrome
    Servier Acquires Potential Treatment for Fragile X Syndrome

    09 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/servier-acquires-potential-treatment-for-fragile-x-syndrome-the-most-common-genetic-cause-of-autism-spectrum-disorder-302548854.html

    PR NEWSWIRE
    09 Sep 2025
    Share Share
    Kaerus Bio's KER-0193 granted Orphan & Rare Pediatric Designation
    Kaerus Bio's KER-0193 granted Orphan & Rare Pediatric Designation

    14 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kaerus-biosciences-lead-candidate-ker-0193-granted-orphan-drug-designation-and-rare-pediatric-drug-designation-by-us-fda-for-treatment-of-fragile-x-syndrome-fxs-302454471.html

    PR NEWSWIRE
    14 May 2025
    Share Share
    Kaerus Bioscience Completes Phase 1 Trial for Fragile X Syndrome
    Kaerus Bioscience Completes Phase 1 Trial for Fragile X Syndrome

    11 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/11/3040590/0/en/Kaerus-Bioscience-Successfully-Completes-Phase-1-Trial-and-Demonstrates-Proof-of-Mechanism-with-its-Novel-BK-Channel-Modulator-KER-0193-being-developed-for-Fragile-X-Syndrome.html

    GLOBENEWSWIRE
    11 Mar 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search